Phase 4 N=30 Envarsus Neurotoxicity Burden in Liver Transplant Patients
Neurotoxicity · Liver Transplant; Complications
Primary: Change in Neurotoxicity Burden — -5; -4 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 CNS Study of Patients Switching From Tacrolimus to Envarsus
Renal Transplant Patients
Primary: Change in Quality of Life — 2.7; 1.35; 0.2 score on a scale
Phase 3 N=319 A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
Cancer
Primary: Neurotoxicity Assessment at Baseline — 8.5; 7.3; 5.23; 4.58 units on a scale
Phase 2 N=36 In Vivo Assessment of Silver Biomaterial Nano-Toxicity
Healthy
Primary: Change in Sodium Blood Levels — -0.1; 0.2 mmol/L
N/A N=63 Chronic Neuropathy Following Chemotherapy
Peripheral Nervous System Diseases · Chronic Pain
Primary: Chemotherapy-induced Peripheral Neuropathy — 21 participants
N/A N=14 Pharmacotoxicology of Trichloroethylene Metabolites
Congenital Lactic Acidosis
Primary: Hypothesize That Subject's Genotype Will Determine How DCA is Metabolized. — 1592; 232 Minutes — p=0.023
N/A N=7 Biomarkers in Chemotherapy-Induced Peripheral Neurotoxicity
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Primary: Relative Change in % pO2 — 12.3; 19; 24; 25.3 change in % oxygenation
Phase 4 N=81 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
Brain Neoplasms · Brain Cancer · Brain Tumors
Primary: Change in Neurotoxicity Scale Scores — -1; -3.5 score on scale — p=0.7824
Phase 2 N=14 Non-intrusive Detection of Temporary Neurologic Impairment By Opioids
Healthy
Primary: Oculo-Cognitive Addition Test (OCAT) Completion Time — 57.22; 57.22; 59.56; 58.18 seconds
Phase 2 N=2 Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy
Peripheral Neuropathy
Primary: Identification of the Optimal Dose of ALA Based on Acceptable Adverse Event(AE) Profile — 500 mg
N/A N=112 Neuroprotective Goal Directed Hemodynamic Optimization in Post-cardiac Arrest Patients
Cerebral Ischemia · Cardiac Arrest
Primary: % of Ischaemic Voxels With an ADC<0.65 mm2/s on Day 4-5 (Diffusion Weighted MRI) — 10.6; 11.0 percentage of ischaemic voxels — p=0.0881
Phase 4 N=16 Neurotoxin and Physical Therapy
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 28; 20.1 total score on a scale
Phase 3 N=353 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
Chemotherapeutic Agent Toxicity · Colorectal Cancer · Neuropathy
Primary: Sensory Area Under the Curve(AUC) Score. Oxaliplatin-induced Sensory Neuropathy as Repeatedly Measured by the EORTC QLQ-CIPN20 Sensory Subscale During Chemotherapy…
Phase 2 N=47 N-Acetylcysteine for Neuroprotection in Parkinson's Disease
Parkinson Disease
Primary: Change of Cerebral Glutathione Levels as Measured by Proton Magnetic Resonance Spectroscopy — 3.422; 3.334; 3.745; 4.282 Ratio
N/A N=20 Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
Multiple Sclerosis
Primary: Change in Cognitive Function Over Time — -1.5; -1.2; -1.2 units on a scale — p=0.17
Phase 2 N=12 In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm
Healthy
Primary: Change Sodium Blood Levels — 141.8; 141.2 mmol/L
N/A N=299 Nucleophilic Defense Against PM Toxicity (NEAT Trial)
Air Pollution Toxicity
Primary: Endothelial Progenitor Cells — 0.0025; 0.0027 # cells per CD41 minus cells
Phase 4 N=64 Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients
Kidney Transplant; Complications · Toxicity · Drug Toxicity
Primary: Change in Neurocognitive Side Effects — 1.2; 0.2; 1.0; 1.26 score on a scale
Phase 2 N=15 Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons
Metastatic Breast Cancer
Primary: Axons With Abnormal Morphology — 52; 82; 2; NA percentage of axons
Phase 3 N=274 Hypovitaminosis D in Neurocritical Patients
Craniocerebral Trauma · Intracranial Aneurysm · Brain Neoplasms
Primary: Intent-to-treat Hospital Length-of-stay — 10.9; 9.1 days — p=0.2
N/A N=46 Neurologic Injuries in Adults With Urea Cycle Disorders
Brain Diseases, Metabolic, Inborn · Urea Cycle Disorder · Ornithine Transcarbamylase Deficiency
Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003
Phase 2 N=5 Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1
Neurofibromatosis 1
Primary: Change From Baseline in Motor Function Measured by Physical and Neurological Examination for Subtle Signs (PANESS) — 0; 3 score on a scale
Phase 2 N=59 The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage
Aneurysmal Subarachnoid Hemorrhage
Primary: Cerebrospinal Fluid 3-aminopropanal (CSF-3AP) Levels — 11.1; 12.9 nmol/mL
Phase 2 N=18 Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: Safety and Tolerability of Drug, Assessed by Change in Methemoglobin Levels — 0.4; 0.5; 0.3; 0.3 Percent of Methemoglobin Level
Phase 3 N=275 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Overactive Bladder
Primary: Change From Baseline in Number of Weekly Episodes of Urinary Incontinence — 31.2; 32.5; 36.7; -19.4 Number of Weekly Episodes
Phase 4 N=210 Effect of IV Acetaminophen on Patients in the Neurocritical Care Unit
Post-operative Craniotomy Patients · Carotid Endarterectomy and Carotid Artery Stenosis Patients · Post-op Spine Patients Admitted to the NCCU
Primary: Narcotic Requirement After Surgery — 123.5; 134.2 Morphine Equivalents
Phase 3 N=102 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
Colorectal Cancer · Neurotoxicity
Primary: Percentage of Patients With Oxaliplatin-induced Grade 2+ Chronic Neuropathic Adverse Event — 22; 41 Percentage of participants — p=0.038
Phase 2 N=185 Evaluating Neuroprotection in Aneurysm Coiling Therapy
Stroke
Primary: Volume of New FLAIR Lesions(MRI) — 915; 477 mm^3 — p=0.445
N/A N=383 Neuroprotection in Patients Undergoing Aortic Valve Replacement
Aortic Stenosis · Brain Infarction · Cerebrovascular Accident
Primary: Percentage of Participants With Freedom From Clinical or Radiographic Central Nervous System (CNS) Infarction — 74.4; 68.0; 67.6 percentage of participants — p=0.22
Phase 2 N=26 Lidocaine for Oxaliplatin-induced Neuropathy
Neuropathy, Painful · Chemotherapy-induced Peripheral Neuropathy · Colorectal Cancer
Primary: Area Under the Curve (AUC) of Intensity of Oxaliplatin-induced Cold Pain/Unpleasantness vs Time — 16.4; 9.5; 33.1; 25.4 score on a scale*days — p=0.318